CA2371114A1 - Recepteurs contenant un domaine de mort cellulaire - Google Patents

Recepteurs contenant un domaine de mort cellulaire Download PDF

Info

Publication number
CA2371114A1
CA2371114A1 CA002371114A CA2371114A CA2371114A1 CA 2371114 A1 CA2371114 A1 CA 2371114A1 CA 002371114 A CA002371114 A CA 002371114A CA 2371114 A CA2371114 A CA 2371114A CA 2371114 A1 CA2371114 A1 CA 2371114A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
amino acid
antibody
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371114A
Other languages
English (en)
Inventor
Guo-Liang Yu
Jian Ni
Reiner L. Gentz
Patrick J. Dillon
Vishva M. Dixit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
University of Michigan
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2371114A1 publication Critical patent/CA2371114A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouvelles protéines de récepteurs contenant un domaine de mort cellulaire (DR3 et DR3-V1), qui sont des membres de la famille des récepteurs du facteur nécrosant des tumeurs (TNF). En particulier, l'invention concerne des molécules d'acides nucléiques isolées qui codent pour les protéines humaines DR3 et DR3-V1. Des polypeptides de DR3 et de DR3-V1 sont également décrits ainsi que des vecteurs, des cellules hôtes et des procédés de recombinaison permettant de produire ceux-ci. L'invention concerne en outre des procédés de criblage pour identifier des agonistes et des antagonistes de l'activité de DR3 et de DR3-V1.
CA002371114A 1999-04-22 2000-04-21 Recepteurs contenant un domaine de mort cellulaire Abandoned CA2371114A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13048899P 1999-04-22 1999-04-22
US60/130,488 1999-04-22
US13674199P 1999-05-28 1999-05-28
US60/136,741 1999-05-28
PCT/US2000/010741 WO2000064465A1 (fr) 1999-04-22 2000-04-21 Recepteurs contenant un domaine de mort cellulaire

Publications (1)

Publication Number Publication Date
CA2371114A1 true CA2371114A1 (fr) 2000-11-02

Family

ID=26828526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371114A Abandoned CA2371114A1 (fr) 1999-04-22 2000-04-21 Recepteurs contenant un domaine de mort cellulaire

Country Status (5)

Country Link
EP (1) EP1178815A4 (fr)
JP (1) JP2003522118A (fr)
AU (1) AU4478200A (fr)
CA (1) CA2371114A1 (fr)
WO (1) WO2000064465A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500702A1 (fr) 1996-04-01 2005-01-26 Genentech, Inc. Polypeptides d'apoptose APO-2LI et APO-3 de la famille de TNFR1
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
MXPA02005069A (es) * 1999-11-19 2003-09-25 Wegmann Keith W Agentes de enlace especificos para t3 y metodos para su uso.
WO2003013581A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Agonistes et antagonistes de la genceptine pour le traitement des troubles metaboliques
EP1361433A3 (fr) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Méthode de detemination l'efficacité d'une TNF thérapie
EP1667730B1 (fr) * 2003-08-20 2013-06-26 University of Miami Compositions et procedes pour le traitement de la maladie pulmonaire inflammatoire
AU2005318086B2 (en) * 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
EP1919954B1 (fr) 2005-08-30 2016-10-19 University of Miami Immunomodulation des agonistes, des antagonistes et des immunotoxines du recepteur 25 du facteur de necrose tumorale (tnfr25)
EP2462165B1 (fr) 2009-08-03 2016-05-11 University of Miami Méthode de prolifération in vivo de cellules t régulatrices
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
CA2897826C (fr) 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions et procedes pour la regulation de lymphocytes t regulateurs a l'aide d'une proteine d'une fusion tl1a-ig
JP2017511381A (ja) * 2014-04-04 2017-04-20 協和発酵キリン株式会社 アゴニスト活性が低減された抗デスレセプター３（ｄｒ３）アンタゴニスト抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
WO1997033904A1 (fr) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
EP1500702A1 (fr) * 1996-04-01 2005-01-26 Genentech, Inc. Polypeptides d'apoptose APO-2LI et APO-3 de la famille de TNFR1
PT1012274E (pt) * 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)

Also Published As

Publication number Publication date
WO2000064465A1 (fr) 2000-11-02
JP2003522118A (ja) 2003-07-22
EP1178815A1 (fr) 2002-02-13
EP1178815A4 (fr) 2003-02-05
AU4478200A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
US8105589B2 (en) Use of DR3 antibodies in the treatment of inflammatory disease
US6902910B2 (en) Death domain containing receptor 4
US7511017B2 (en) Methods of treatment with TNFR5
US7186800B1 (en) Tumor necrosis factor 6α and 6β
US6919078B2 (en) Antibodies to human tumor necrosis factor receptor TR9
US7452538B2 (en) Death domain containing receptor 4 antibodies and methods
US7476384B2 (en) Death domain containing receptor 4 antibody and methods
US7709218B2 (en) Tumor necrosis factor receptors 6α and 6β
US20050282217A1 (en) Human tumor necrosis factor receptor TR10
US20060234285A1 (en) Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta
CA2371114A1 (fr) Recepteurs contenant un domaine de mort cellulaire
WO2000067793A9 (fr) Recepteur 4 contenant le domaine de la mort cellulaire programmee
US6713061B1 (en) Death domain containing receptors
EP1159286A1 (fr) Recepteurs du facteur de necrose tumorale 6 alpha et 6 beta
EP1191940A1 (fr) Recepteur 5 du facteur de necrose tumorale
WO2000056862A1 (fr) Recepteur tr9 humain de facteurs de necrose des tumeurs
US20020098163A1 (en) Human tumor necrosis factor receptors TR21 and TR22
CA2420593A1 (fr) Recepteurs du facteur de necrose tumorale 6$g(a) et 6$g(b)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead